Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of V116 versus PCV15 + PPSV23 in adults living with HIV
2021-006710-36Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pneumococcal disease comparing V116 with PCV15 + PPSV23 (2 arms). Primary endpoint: Percentage of participants with solicited injection-site adverse events. Started Jun 2022; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccinepneumococcal conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2021-006710-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006710-36.